儿科自身免疫或原发性硬化胆管炎:对生物化学数据,胆酸概况和肠道微生物群的甲尼达疗效:试点研究
Manon Karemera1, Marko Verce2, Martin Roumain3
1From the Department of Pediatrics, Division of Pediatric Gastroenterology and Hepatology, Cliniques universitaires Saint-Luc, Brussels, Belgium.
JPGN reports
|August 21, 2023
概括
甲尼达 (MTZ) 可能通过改善生化标志物和增加有益的胆酸 (BAs) 来改善早期自身免疫性硬化胆炎 (ASC) 或初级硬化胆炎 (PSC) 的益处. 需要进一步的多中心研究来证实这些发现.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 胃肠病学 胃肠病学
- 微生物组研究的研究.
背景情况:
- 自身免疫性肝炎和原发性硬化胆炎 (PSC) 可以同时存在于自身免疫性硬化胆炎 (ASC).
- 肠道微生物群和胆酸 (BA) 相互作用与PSC病变发生有关.
- 抗生素代表了这些疾病的潜在治疗途径.
研究的目的:
- 为了评估在ASC或PSC患者中甲二醇 (MTZ) 的疗效.
- 评估MTZ对疾病阶段,生物化学参数,BA概况和肠道微生物群的影响.
- 探索MTZ治疗的潜在长期益处.
主要方法:
- 一项试点研究涉及18名儿科患者 (13名ASC,5名PSC) 用MTZ治疗至少14天.
- 以合并数据集进行回顾性和前性数据收集.
- 生物化学标志物 (AST,ALT,GGT,CRP) 和BA概况在MTZ治疗前后进行分析.
主要成果:
- 在大多数患者中,MTZ的使用导致CRP,AST,ALT和GGT水平降低.
- 在基线和治疗后观察到AST和ALT的显著降低.
- 缓解期患者在MTZ后表现出水友性胆酸的增加,而肠道微生物群的组成保持不变.
结论:
- 对于早期ASC或PSC患者来说,MTZ治疗可能会带来长期益处.
- 在缓解期患者的MTZ治疗中,增加了性胆酸丰度.
- 需要进一步的多中心前性研究来验证这些发现.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Drugs for Treatment of Ulcerative Colitis in IBD
173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
355
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
355
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
157
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
157
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195


